Core Insights - Novartis will participate in the 8th China International Import Expo, marking its eighth consecutive appearance, emphasizing its commitment to becoming China's most valuable and trusted healthcare partner [1][2] Group 1: Innovation Focus - The "Focus on Innovation" exhibition area will showcase nearly 20 innovative products across four core therapeutic areas: cardiovascular, renal and metabolic, oncology, immunology, and neuroscience [1] - Attendees will have the opportunity to experience award-winning products and new indications for blockbuster drugs, including targeted therapies for cancer and innovative renal treatment pipelines [1] - An immersive interactive experience using advanced spatial computing display technology will allow visitors to explore the journey of innovative drugs within the human body [1] Group 2: Commitment to China - The "Deepening in China" exhibition area will reflect Novartis's century-long relationship with China and its new vision for development in the country [2] - Since 2018, Novartis has aligned its growth strategy with the Import Expo, increasing investments and fostering trust within the industry to contribute sustainably to China's innovative pharmaceutical ecosystem [2] Group 3: Accessibility of Medicine - The "Pharmaceutical Accessibility" exhibition area will highlight Novartis's efforts to enhance medicine accessibility for Chinese patients [2] - The area will showcase collaborations with partners in the pharmaceutical ecosystem, focusing on integrating innovative drugs into the national medical insurance directory and exploring diverse solutions for improving medicine accessibility [2] - A giant curved screen at the exhibition will inspire attendees to envision the future of healthcare through advanced pharmaceutical technologies [2]

Earnings Reports Overview - Next Wednesday and Thursday are significant earnings days with over 39 reports each [1] - Major tech companies reporting next Wednesday include Microsoft Corporation, Alphabet Inc., and Meta Platforms Inc. after market close [1] - On Thursday, Apple Inc. and Amazon.com Inc. are expected to be major market movers, alongside pre-market reports from Eli Lilly and Company and Merck & Company Inc. [1] - Next Friday, energy companies Exxon Mobil Corporation and Chevron Corporation will report before market open [1] - Major healthcare companies UnitedHealth Group Incorporated and Novartis AG will report pre-market next Tuesday, while Visa Inc. will report after market close [1]

Core Viewpoint - Analysts project Novartis (NVS) will report quarterly earnings of $2.26 per share, reflecting a 9.7% year-over-year increase, with revenues expected to reach $13.9 billion, an 8.4% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [1][2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [2]. Revenue Projections - Analysts expect 'Revenues- Oncology- Tafinlar + Mekinist- Total' to be $555.75 million, a 4.1% increase year-over-year [4]. - 'Revenues- Net sales to third parties' are projected to reach $14.07 billion, indicating a 9.8% year-over-year change [4]. - 'Revenues- Oncology- Kisqali- Total' is estimated at $1.29 billion, reflecting a significant 64.2% year-over-year increase [4]. Specific Revenue Metrics - 'Revenues- Immunology- Cosentyx- Total' is expected to reach $1.72 billion, a 1.9% increase from the prior year [5]. - 'Revenues- Oncology- Tasigna- US' is projected at $119.43 million, showing a decline of 47.2% year-over-year [5]. - 'Revenues- Oncology- Promacta/Revolade- US' is estimated at $180.08 million, indicating a 41.2% decrease from the year-ago quarter [5]. Additional Revenue Insights - 'Revenues- Immunology- Cosentyx- US' is expected to be $990.42 million, a slight decrease of 0.3% year-over-year [6]. - 'Revenues- Cardiovascular- Entresto- US' is projected at $927.94 million, reflecting a 1.8% increase from the previous year [6]. - 'Revenues- Oncology- Tasigna- ROW' is estimated at $149.03 million, indicating a 22.8% decline year-over-year [7]. - 'Revenues- Oncology- Tafinlar + Mekinist- ROW' is expected to reach $320.55 million, a 4.4% increase year-over-year [7]. - 'Revenues- Oncology- Promacta/Revolade- ROW' is projected at $267.72 million, reflecting a 1.8% increase [7]. - 'Revenues- Immunology- Cosentyx- ROW' is expected to be $734.58 million, indicating a 4.9% increase from the prior year [8]. Stock Performance - Novartis shares have increased by 6.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a 0.2% increase [8].

Core Viewpoint - Investors are seeking growth stocks that can deliver above-average growth and exceptional returns, but identifying such stocks can be challenging due to inherent volatility and risks [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system helps identify cutting-edge growth stocks by analyzing real growth prospects beyond traditional attributes [2] - Novartis (NVS) is currently recommended due to its favorable Growth Score and top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive [4] - Novartis has a historical EPS growth rate of 7.9%, but projected EPS growth for this year is 14.4%, surpassing the industry average of 11.7% [5] Group 3: Asset Utilization - The asset utilization ratio (sales-to-total-assets ratio) is an important metric for growth stocks, indicating efficiency in generating sales [6] - Novartis has an S/TA ratio of 0.52, outperforming the industry average of 0.47, indicating better efficiency [6] Group 4: Sales Growth - Sales growth is another key factor, with Novartis expected to achieve 8.4% sales growth this year, compared to the industry average of 6.8% [7] Group 5: Earnings Estimate Revisions - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [8] - Current-year earnings estimates for Novartis have been revised upward, with the Zacks Consensus Estimate increasing by 0.2% over the past month [9] Group 6: Overall Assessment - Novartis has earned a Growth Score of B and a Zacks Rank 2 due to positive earnings estimate revisions, indicating it is a potential outperformer and a solid choice for growth investors [11]

Core Insights - Novartis announced that Cosentyx® (secukinumab) achieved significant results in the Phase III REPLENISH trial for treating polymyalgia rheumatica (PMR), meeting both primary and secondary endpoints [1][7] - The trial demonstrated that Cosentyx provided sustained remission compared to placebo at Week 52, indicating its potential as a novel treatment option for PMR [1][7] Company Overview - Novartis is an innovative medicines company focused on improving and extending patients' lives through advanced therapies, reaching nearly 300 million people globally [9] Product Information - Cosentyx is a fully human biologic that inhibits interleukin-17A, a key cytokine in various immune-mediated inflammatory diseases, and is already approved for multiple conditions including psoriatic arthritis and ankylosing spondylitis [4] - Since its launch in 2015, Cosentyx has treated over 1.8 million patients worldwide and is approved in more than 100 countries [4] Clinical Trial Details - The REPLENISH trial was a global Phase III, multicenter, randomized, double-blind, placebo-controlled study conducted in 27 countries, assessing the efficacy and safety of Cosentyx in PMR patients [3] - The primary endpoint was to determine if secukinumab 300mg plus a steroid taper was superior to placebo plus a steroid taper in achieving sustained remission at Week 52 [3] Disease Context - Polymyalgia rheumatica is the second most common inflammatory rheumatic disease in adults aged 50 and older, characterized by significant pain and stiffness, which can severely impact quality of life [5] - Long-term steroid use, the standard treatment, poses risks such as osteoporosis and diabetes, highlighting the need for effective alternatives like Cosentyx [5]

Core Points - Novartis announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act in relation to its tender offer to acquire Tourmaline Bio at a price of $48.00 per share in cash [1][2] - The expiration of the HSR Act waiting period is a necessary condition for the completion of the merger agreement dated September 8, 2025, which includes the tender offer and subsequent merger [2] - The tender offer will expire at 11:59 p.m. Eastern Time on October 27, 2025, unless extended or terminated earlier [2] Company Information - Novartis is an innovative medicines company focused on improving and extending people's lives through its products, reaching over 300 million people globally [7]

Group 1 - Chronic diseases account for 88.5% of total deaths in China, with cardiovascular diseases, cancer, and diabetes being the primary burdens [1] - The total number of cardiovascular disease patients in China is approximately 330 million, creating significant economic pressure on families and the healthcare system [1] - Novartis has proposed a digital blueprint for lipid management and cardiovascular prevention in Shanghai, aiming to establish an AI-driven health management system for city residents [1] Group 2 - The management of chronic diseases requires multi-departmental collaboration and public participation, as emphasized by Wu Jing, Director of the Chronic Disease Center at the Chinese CDC [2] - AstraZeneca has supported over ten basic research projects in the fields of oncology, chronic diseases, and rare diseases through its China Translational Medicine Research Fund [2] - AstraZeneca has initiated a "China Postdoctoral Program" to support future scientific leaders and enhance local research innovation capabilities in chronic and rare diseases [2] Group 3 - China has accumulated rich resources and experience in respiratory diseases and possesses internationally recognized disease cohorts and biobanks, which can support global target discovery and translational research [3]

Core Insights - Swiss drugmaker Novartis announced that its targeted radiotherapy treatment Pluvicto has demonstrated a 28% reduction in the risk of progression or death in patients with prostate cancer [1] Company Summary - Novartis is focusing on innovative treatments for cancer, with Pluvicto being a significant advancement in targeted radiotherapy [1] Industry Summary - The announcement highlights the ongoing advancements in cancer treatment, particularly in targeted therapies, which are becoming increasingly important in improving patient outcomes [1]

Core Insights - Novartis presented new data on Pluvicto™ at the ESMO Congress 2025, highlighting its efficacy in treating metastatic hormone-sensitive prostate cancer [1][5] Efficacy of Pluvicto - Pluvicto combined with standard of care (SoC) showed a 28% reduction in the risk of radiographic progression or death compared to SoC alone in patients with PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC) [2][7] - An early positive trend in overall survival was observed with a hazard ratio (HR) of 0.84, indicating potential benefits in long-term outcomes [3][7] - The overall response rate (ORR) was higher in the Pluvicto plus SoC group (85.3%) compared to SoC alone (80.8%) [3][7] Safety Profile - The safety profile of Pluvicto was consistent with previous studies, with grade ≥3 adverse events reported in 50.7% of patients receiving Pluvicto plus SoC, compared to 43% in the SoC group [4][7] - Common adverse events included dry mouth, fatigue, nausea, hot flush, and anemia [4] Regulatory and Market Implications - PSMAddition marks the third positive Phase III trial for Pluvicto, reinforcing its potential to improve outcomes in earlier stages of metastatic prostate cancer [5][7] - Novartis plans to submit these findings to regulatory authorities by the end of the year, which could double the number of patients eligible for Pluvicto [7] Unmet Need in mHSPC - Approximately 172,000 men are diagnosed with mHSPC annually in major markets, with most progressing to metastatic castration-resistant prostate cancer (mCRPC) within 20 months [6] - The progression to mCRPC is associated with significantly worse outcomes, highlighting the urgent need for effective therapies [6][7] About Pluvicto - Pluvicto is a radioligand therapy that targets PSMA-expressing cells, delivering treatment directly to cancer cells [9][10] - It is the only PSMA-targeted agent approved for PSMA+ mCRPC and has shown clinical benefits in mHSPC [10] Novartis and RLT - Novartis is advancing cancer care through radioligand therapy (RLT), focusing on targeted radiation to treat advanced cancers [11] - The company is expanding its RLT manufacturing capabilities to meet growing demand [11]

Core Insights - Novartis presented new data on Pluvicto™ from the Phase III PSMAddition trial, showing significant improvements in treatment outcomes for patients with metastatic hormone-sensitive prostate cancer [1][5]. Efficacy of Pluvicto - Pluvicto combined with standard of care (SoC) reduced the risk of radiographic progression or death by 28% (HR 0.72; 95% CI: 0.58, 0.90) compared to SoC alone in patients with PSMA+ metastatic hormone-sensitive prostate cancer [2][6]. - An early positive trend in overall survival (OS) was observed with a hazard ratio of 0.84 (95% CI: 0.63, 1.13) for patients treated with Pluvicto plus SoC [3][6]. - The complete response rate was higher in the Pluvicto plus SoC group (57.1%) compared to SoC alone (42.3%), and the overall response rate was also numerically higher (85.3% vs. 80.8%) [3][6]. - Pluvicto delayed progression to metastatic castration-resistant prostate cancer (mCRPC) with a hazard ratio of 0.70 (95% CI: 0.58, 0.84) [3][6]. Safety Profile - The safety profile of Pluvicto was consistent with previous studies, with grade ≥3 adverse events reported in 50.7% of patients in the Pluvicto plus SoC arm compared to 43% in the SoC alone group [4][6]. - Common adverse events included dry mouth, fatigue, nausea, hot flush, and anemia [4][6]. Regulatory and Market Implications - PSMAddition is the third positive Phase III trial for Pluvicto, building on previous successes that led to FDA approval for mCRPC in March 2025 [5][6]. - Novartis plans to submit the new data to regulatory authorities by the end of the year, which could potentially double the number of patients eligible for Pluvicto [5][6]. Unmet Medical Need - Approximately 172,000 men are diagnosed with metastatic hormone-sensitive prostate cancer annually in major markets, highlighting the urgent need for effective therapies [6][7]. - Most patients with this condition progress to mCRPC, which is associated with significantly worse outcomes and a life expectancy of less than two years [7][6]. About Pluvicto - Pluvicto is a radioligand therapy that targets PSMA-expressing cells, delivering treatment directly to prostate cancer cells [9][10]. - It is the only PSMA-targeted agent approved for PSMA+ mCRPC and the first to show clinical benefit in mHSPC in a Phase III trial [10]. Novartis and Radioligand Therapy - Novartis is advancing cancer care through radioligand therapy, focusing on targeted radiation to treat advanced cancers [11]. - The company is expanding its RLT manufacturing capabilities to meet growing demand and is exploring new isotopes and combination therapies for various cancers [11].